



## PROGRAM (English)

### [Global Medicinal Cannabis Academia ©](#)

### International Medical Cannabis Competence Center

FIRST SEMESTER 24.02. – 19.03.2026

**32 study hours, certified program,  
Level National Professional Qualification,  
Recognized Credit Points (32) for Doctors of the Medical Chamber of Slovenia**

**Translations of lecture recordings English - Slovenian / Slovenian - English  
Audiobook of lectures in English  
Recommended professional materials**

**Training price € 1,500.00 per participant with certificate**

#### **24.02.2026 (day 1) at 10.00 h**

#### **History of Cannabis Use for Medical Purposes and Trends (3 hours)**

**Dr. Tina Mele - SLOVENIA EU**

Through the history of the use of cannabis for medical purposes, we can learn a lot about the plant itself and its effects; especially since in the mid-20th century it was persecuted as an unwanted plant for various reasons and so we do not have any "modern" research or records about its effects. However, before that, it was a highly valued medicinal plant and at the turn of the 19th and 20th centuries, more than 100 scientific articles were published about the cannabis plant, international conferences were also organized on the topic of the use of cannabis and we can learn a lot from these records and data. Until 1941, cannabis was also included as a plant in the United States Pharmacopeia (the reasons why it was removed are still hotly debated) and had officially confirmed indications for its use. With the resurgence of its use for medicinal purposes around the world, we are seeing similar "patterns" as those observed in the past.

So, the history of cannabis use for medicinal purposes can tell us a lot about when and how to use cannabis as a whole plant for medicinal purposes.

#### **25.02.2026 (day 2) at 10.00 h**

#### **Mechanism of Action of Cannabis as a Whole Plant (3 hours)**

**Dr. Tina Mele SLOVENIA EU**

Cannabis is much more than just THC and CBD. Using the whole plant compared to isolated or synthetic active ingredients brings the advantages of synergy and therefore often the need for psychoactive THC (which can bring with it the side effects of

intoxication) is lower and the use of the whole plant is therefore safer than isolated or synthetic active ingredients. Other cannabinoids and their acid forms, terpenes and flavonoids, which cannabis contains and which bring many benefits to our health, are also being slowly researched.

When prescribing cannabis as a medicine, we cannot ignore understanding the endocannabinoid system, which is one of the main regulatory systems in our body (but it is often not mentioned in medical books), so in this lecture we will look at the functioning of this system and how cannabis as a whole plant can benefit us.

**26.02.2026 (day 3) at 16.00 h**

### **Studies of Prenylated Flavonoids, Terpenes and Other Medicinal Substances in Medical Cannabis (1 hour)**

**Prof. Dr. Samo Kreft, mag. pharm. - SLOVENIA EU**

Studies of Prenylated Flavonoids, Terpenes and Other Medicinal Substances in Medical Cannabis

This lecture outlines the biosynthetic origins and structures of key non-cannabinoid constituents in cannabis. We focus on prenylated flavonoids (e.g., cannflavins) formed via phenylpropanoid–flavonoid pathways with O- and C-prenylation by aromatic prenyltransferases, and on mono-/sesquiterpenes arising from MEP/MVA pathways. We discuss how prenylation modulates physico-chemical, pharmacological properties (lipophilicity, membrane affinity, stability), and summarize processing effects (drying, storage) on profiles. Methods include LC-MS for phenolics and GC-MS for volatiles. Emphasis is on chemovar variability, standardization, and clear chemical nomenclature.

**26.02.2026 (day 3) at 17.00 h**

### **Acidic and non-acidic cannabinoids as medicinal substances in cannabis (1 hour)**

**Prof. Dr. Samo Kreft, mag. pharm. - SLOVENIA EU**

We examine the chemical system of acidic vs. neutral cannabinoids. CBGA arises from olivetolic acid + GPP; dedicated synthases yield THCA, CBDA, CBCA, which undergo decarboxylation to THC, CBD, CBC. The talk compares structures, tautomerism and isomerization risks, oxidation pathways (e.g., to quinones), and stability under heat, light, oxygen, moisture. We review partitioning/solubility in oils vs. aqueous media, matrix effects in preparations, and practical quantification by HPLC/LC-MS with attention to sample handling to avoid in-vitro decarboxylation. The emphasis is conceptual: biosynthesis–structure–property relationships, labeling that distinguishes acidic/neutral content, and implications for reproducible composition.

**26.02.2026 (day 3) 18.00 h (USA LA THU / 9.00 h)**

### **Cannabinol (CBN) Ameliorates Age-Related Cognitive Decline by Improving the Health of Synaptic and Mitochondrial Connections (1 hour)**

**Dr. Pamela Maher - UNITED STATES OF AMERICA**

**03.03.2026 (day 4) 16.00 h (USA VA TUE / 7.00 h)**

### **Discovery and Function of CB2 Cannabinoid Receptors (1 hour)**

**Dr. Philip Blair – UNITED STATES OF AMERICA**

Recent research has confirmed the presence of functional CB2 receptors (CB2Rs) in the brain, challenging previous beliefs that they were only peripheral receptors. This discovery opens new avenues for therapeutic targeting in CNS disorders.

- Previous studies suggested CB2Rs were absent in the brain, labeling them as peripheral receptors.
- New evidence shows CB2Rs are expressed in microglia and neurons in various brain regions.
- Functional CB2Rs are involved in neuroinflammation and may play a role in treating CNS disorders.
- The debate over the presence of CB2Rs in the brain continues despite substantial evidence supporting their existence.

**03.03.2026 (day 4) 17.00 h (USA VA TUE / 8.00 h)**

### **Therapeutic Potential of Targeting CB2Rs (1 hour)**

**Dr. Philip Blair – UNITED STATES OF AMERICA**

Targeting CB2Rs presents a promising approach for treating CNS disorders with fewer adverse effects compared to CB1R targeting. This potential is particularly relevant for conditions associated with neuroinflammation.

- CB2R activation is linked to reduced adverse effects compared to CB1R activation.
- CB2Rs are involved in regulating neuroinflammation, which is a key factor in many CNS disorders.

- Research indicates that CB2R agonists may provide therapeutic benefits without intoxicating effects.
- The role of CB2Rs in various disorders, including anxiety, depression, and addiction, is being increasingly recognized.

**03.03.2026 (day 4) 18.00 h (USA VA THU / 9.00 h)**

**Mechanisms of CB2R Signaling in the CNS** (1 hour)

**Dr. Philip Blair – UNITED STATES OF AMERICA**

CB2R signaling involves complex pathways that can influence various physiological and pathological processes in the CNS. Understanding these mechanisms is essential for developing targeted therapies.

- CB2R activation inhibits adenylyl cyclase activity and initiates MAPK and PI3K-Akt pathways.
- The activation of CB2Rs can lead to diverse outcomes, including modulation of metabolism and immune response.
- CB2Rs are primarily expressed post-synaptically and can inhibit postsynaptic neuronal function.
- The inducible nature of CB2Rs during inflammation highlights their potential as therapeutic targets in neuroinflammatory conditions.

**04.03.2026 (day 5) 10.00 h**

**The Action and Use of THC** (2 hours)

**Dr. Tina Mele - SLOVENIA - EU**

Research often focuses on a single active ingredient due to "simplicity" and reproducibility of results, and so we have quite a bit of research and data on the action of THC, and although the cannabis plant is much more than just THC, to understand its action it is also necessary to know what science has found out about the action of THC itself and its effects. Advantages and disadvantages of THC or dangers and precautions. When is THC beneficial to us in preparations and when is it not.

**04.03.2026 (day 5) 12.00 h**

**The Action and Use of CBD** (2 hours)

**Dr. Tina Mele - SLOVENIA – EU**

CBD, which is a non-psychoactive active ingredient of cannabis, is most often discussed in scientific circles when it comes to certain forms of epilepsy, which is not only anecdotal, but also a scientifically confirmed and very effectively used medicine or preparations in Slovenia.

But CBD also has enormous potential in other areas, such as anxiety. There is also a flood of CBD products on the market that need critical assessment. CBD works in many ways

**05.03.2026 (day 6) 10.00 h (AU SY TUE / 19.00 h)**

**The use of medical cannabis in the treatment of anxiety** (1 hour)

**Dr. Kylie O'Brien PhD – AUSTRALIA**

In this presentation, Professor O'Brien will discuss how the endocannabinoid system (ECS) is involved in the regulation of stress and emotions, what changes occur in the ECS in anxiety, and why medicinal cannabis might be useful in treating anxiety. The scientific evidence base, including preclinical research and human research investigating the effectiveness/efficacy of medicinal cannabis and several of its key components in anxiety will be explored.

**05.03.2026 (day 6) 17.00 h (USA VA TUE / 9.00 h)**

**CB2R-ECS in Addiction and Substance Use Disorders** (1 hour)

**Dr. Philip Blair – UNITED STATES OF AMERICA**

The ECS, particularly CB2Rs, is implicated in the mechanisms of addiction and substance use disorders, including alcohol and drug addiction. Targeting CB2Rs may offer new therapeutic strategies for managing addiction.

**10.03.2026 (day 7) 10.00 h**

### **Methods of cultivation and processing of medical cannabis to ensure clinical quality (1 hour)**

**M.Sc. Majda Robić - SLOVENIA EU**

The cannabis industry is transitioning from the black market to the legal market, so product development and extraction methods have become a central focus. To date, more than a thousand chemical compounds have been identified in the cannabis plant, all with different chemical properties, the production and preservation of which require high standards, which require different storage conditions during drying and extraction, and first and foremost, healthy, clean and professional cultivation without pesticides, which is key to the healthy and safe use of cannabis, as required by the specifics of the individual disease and patient.

**10.03.2026 (day 7) 11.00 h**

### **International introduction to the medical cannabis market and business (1 hour)**

**M.Sc. Majda Robić - SLOVENIA EU**

A global overview of the medical cannabis market is essential for understanding not only the pharmaceutical business but also the treatment and prescription of medical cannabis. The global medical cannabis market, estimated at USD 21.33 billion in 2024, is expected to reach USD 27.81 billion in 2025 and exceed USD 211.54 billion by 2035, representing a 22.5% annual growth rate over the forecast period, is a capital that deeply affects the movements of the local and international economy, the market and import strategies and supplies for the purpose of treatment of an individual country, healthcare and pharmaceuticals, which is still legally very limited and specific.

### **Medical Cannabis Act for Slovenian Doctors**

**Charles Kovess, LL.B. (Hons), LL.M., CSP, KSJ - AUSTRALIA**

"Legal Framework and Professional Responsibility in Prescribing Medical Cannabis: A Comprehensive Guide for Slovenian Doctors" will be presented by one of the most prominent international lawyers who, together with the international profession, creates and defends the medical cannabis environment, attorney Charles Kovess, LL.B. (Hons), LL.M., CSP, KSJ. Attorney Charles Kovess, will expertly present and educate participants on the key legal points that every physician in the domestic and international healthcare business environment must know in order to:

- Prescribe medical cannabis in full compliance with Slovenian law
- Avoid negligence claims with appropriate risk management
- Obtain and document valid informed consent
- Create defensible medical records
- Resolve complications with appropriate legal responses
- Understand international legal complexities
- Meet all regulatory and reporting obligations

#### KEY TOPICS

- Slovenian legislation on medical cannabis, after the referendum will of the Cannabis for Medical and Scientific Purposes final Act
- EU regulatory frameworks and EMA-approved products
- The four elements of medical negligence and how to prevent them
- Special populations: pediatric, geriatric, pregnancy, psychiatric
- Cannabis-specific informed consent requirements
- Documentation standards and GDPR compliance
- Management adverse effects: poisoning, hyperemesis, use disorder
- Product quality, contamination risks and liability
- International legal models (Canada, USA, Israel, Germany)
- Labor, insurance and employment law issues

#### UNIQUE VALUE OFFER

This course uniquely combines:

- Legal knowledge from internationally recognized lawyers
- Practical application in everyday clinical practice
- Slovenia-specific content based on new national legislation
- EU perspective for cross-border understanding
- Focus on risk management to protect physicians from liability with the possibility of legal advice in the medical profession
- An approach based on evidence and international experience Legal foundations of medical cannabis in Slovenia and the EU

**11.03.2026 (day 8) 10.00 h (AU SY / WED / 20.00 h)**

**Overview of new Slovenian and European legal regulations**

*International legal frameworks in the environment of medical cannabis treatment (1 hour)*

Charles Kovess, LL.B. (Hons), LL.M., CSP, KSJ - AUSTRALIA

**11.03.2026 (day 8) 11.00 h (AU SY / WED / 21.00 h)**

**Professional responsibility and duty of care in medical cannabis**

*Understanding negligence, standard of care and strategies for preventing liability (1 hour)*

Charles Kovess, LL.B. (Hons), LL.M., CSP, KSJ - AUSTRALIA

**12.03.2026 (day 9) 10.00 h (AU SY / THU / 20.00 h)**

**Informed consent and patient rights in cannabis treatment**

*Legal requirements for consent, patient autonomy and documentation (1 hour)*

Charles Kovess, LL.B. (Hons), LL.M., CSP, KSJ - AUSTRALIA

**12.03.2026 (day 9) 11.00 h (AU SY / THU / 21.00 h)**

**Documentation Standards and Legal Defense**

*Creating Legally Sound Medical Records That Protect Both Patient and Physician (1 hour)*

Charles Kovess, LL.B. (Hons), LL.M., CSP, KSJ - AUSTRALIA

**17.03.2026 (day 10) 10.00 h (AU SY / TUE / 20.00 h)**

**Managing Complications, Adverse Events, and Legal Liabilities**

*Addressing Cannabis-Related Complications, Mandatory Reporting, and Product Liability (1 hour)*

Charles Kovess, LL.B. (Hons), LL.M., CSP, KSJ - AUSTRALIA

**17.03.2026 (day 10) 11.00 h (AU SY / THU / 21.00h)**

**International Perspectives and Future Legal Challenges**

*Global Legal Frameworks, Cross-Border Issues, and Preparing for Regulatory Development (1 hour)*

Charles Kovess, LL.B. (Hons), LL.M., CSP, KSJ – AUSTRALIA

**18.03.2026 (day 11)**

**Consultations between lecturers and participants and replacement of missed lectures**

(Dr. Mikael Kowal / Dr. Tanja Bagar )(3 hours)

Expert discussion

Detailed information later

**19.03.2026 (day 12)**

**Consultations between lecturers and participants and replacement of missed lectures**

(Dr. Mikael Kowal / Dr. Tanja Bagar )(3 hours)

Expert discussion

Detailed information later

\*\*\*

## Global Medicinal Cannabis Academia Team

### **Medicinal Cannabis**

Senior Professional lecturer & Doctor of Medicine

**Dr. Kylie O'Brien, PhD**

#### **AUSTRALIA**

Professor Kylie O'Brien is, Doctor of Chinese Medicine and Science (Chin Med), MPH, BAppSc(Chin Med), BSc(Optomety), Grad Cert Tertiary Education.

Trained originally as an optometrist, after 15 years in clinical practice Kylie career-changed to Chinese medicine (CM), developing a career as an academic in CM. She developed the curricula for three Master degrees in CM, and was the Course Coordinator for Victoria University's undergraduate and Western Sydney University Masters courses in CM. Subsequent roles as Associate Dean (Teaching and Learning) at Victoria University, Director of Assessment and Learning Design (Deakin University), National Academic Director (AIAS), Director of Education (National Institute of Integrative Medicine) and Director of Education (Australasian College of Nutritional and Environmental Medicine) equipped her with a deep understanding and strong leadership skills in tertiary education. She entered the medicinal cannabis industry in 2018 and became one of Australia's leading educators in this field. She is actively involved in clinical research into medicinal cannabis, and has authored three books: O'Brien and Sali, A Clinicians Guide to Integrative Medicine, Springer 2017; O'Brien and Blair, Medicinal Cannabis and CBD in Mental Healthcare, Springer 2021 and O'Brien and Bosak, Medicinal Cannabis in Women's Health, Springer 2025. She is an Adjunct Professor at Torrens University and an Adjunct Associate Professor at NICM Health Research Institute, (Western Sydney University) and is a member of the Australian government's TEQSA Expert Panel.

### **Medicinal Cannabis**

Senior Professional lecturer Doctor of Medicine

**Dr. Philip W. Blair PhD**

#### **UNITED STATES OF AMERICA**

COL Philip Blair, MD, graduated from West Point '72, trained in Family Medicine, served as a combat physician in Gulf War and retired after 25 years. He managed complex diseases for 15 years and since 2014 he has been treating, consulting and lecturing on the endocannabinoid system and nonpsychoactive cannabidiol. [50] Dr. Philip Blair, MD, (Colonel USArmy) graduated from West Point '72, was a combat physician and retired after 25 years. He managed complex diseases for 15 years and since 2014 has treated, consulted and lectured on the endocannabinoid system and cannabidiol from hemp. He has consulted with patients, parents and professionals worldwide about CBD. In 2021 he coauthored the Medicinal Cannabis and CBD in Mental Healthcare and developed BCPLus, a non-cannabis CB2R activator. (74w) Dr. Philip Blair, MD, (Colonel USArmy retired) is a Family Physician and consultant in disease management in the Northwest. He graduated from West Point 1972 and University of Miami School of Medicine 1978, trained in Family Medicine and served as combat physician in 1990-1991 Gulf War. After medical assignments in three continents and 25 years in uniform he retired from the Army and has been consulting on complex disease management. Since 2014 Dr. Blair has been studying, treating, writing and lecturing about cannabidiol and the human body's natural endocannabinoid system (ECS). ECS dysfunction appears closely associated with the full range of chronic illness. His goal is to restore health and performance by enhancing the ECS through diet, exercise, appropriate medications and non-psychoactive herbs. In 2021 he coauthored the Medicinal Cannabis and CBD in Mental Healthcare and developed BCPLus, an oral non-cannabis CB2R activator from caryophyllene. [148w]

### **Medicinal Cannabis**

Senior Professional Lecturer & Researcher

**Dr. Tina Mele**

#### **SLOVENIA – EU**

Dr. Tina Mele, is a Doctor of Veterinary Medicine and Doctor of Medical Sciences, an herbalist, a wise woman and one of the greatest experts in green natural medicine and the use of wild food. Dr. Mele, completed her doctoral dissertation at the Faculty of Medicine, in the field of Pharmacology. She presented her research on cannabis in the academic article "New indications and development of Cannabis - based medicines". Dr. Mele works as a professor of Biopsychology at the University of Primorska in

Slovenia. She currently researches and lectures on professional topics such as the integration of herbal medicine in the environment of science and tradition, herbal medicine, medicine for people and scientific achievements, and she is a professional advocate for topics related to medical cannabis.

### **Medicinal Cannabis**

**Senior Professional Researcher**

**Doc. Dr. Tanja Bagar**

**SLOVENIA - EU**

Dr. Tanja Bagar, is the director of the Icanna Institute and an assistant professor at Alma Mater Europaea - ECM. She graduated in microbiology and later received a PhD in Biomedicine, majoring in Molecular Biology and Biochemistry, and has experience in clinical microbiology, research biotechnology, ecology, and teaching. She has been teaching microbiology and biochemistry and other ecological topics to students for many years. She is interested in what happens in the microscopic cells of our body, how cells cooperate and communicate with each other, and also how external factors affect our body. From food and toxins to touch. Cannabis in Medicine is a pioneering book by Dr. Tanja Bagar, with the authority of an established scientist in the field of biomedicine, convincingly presents the scientific foundations of the use of cannabis in medicine, where, through scientific facts about the functioning of the body at the cellular level, she explains to both laypeople and high-level professionals how the endocannabinoid system is expressed in the body and thus influences its functioning through risks, safe use and dosage.

### **Medicinal Cannabis**

**Senior Scientist**

**PhD Mikael Kowal**

**NETHERLANDS -EU**

Mikael Kowal, has been working in the medicinal cannabis industry since 2014. He previously completed his PhD at Leiden University in the Netherlands on the topic of psychopharmacology of cannabis. Over the years Mikael has been involved in the conduct of several clinical trials with cannabis. More recently, he has been actively setting up an internal scientific research program. Mikael is interested in exploring the full medical potential of the cannabis plant, while acknowledging the limitations and risks of treatment with cannabis.

### **Medicinal Cannabis**

**Senior Research Professor**

**Cellular Neurobiology Laboratory**

**Pamela Maher, PhD**

**UNITED STATES OF AMERICA**

Pamela Maher, received her BSc from McGill University in Montreal, Quebec and her PhD from the University of British Columbia in Vancouver, British Columbia. She is currently a Research Professor and head of the Cellular Neurobiology Laboratory at The Salk Institute in La Jolla, CA. Her research interests include models and mechanisms of cell death in aging and neurodegenerative diseases with a specific focus on the oxytosis/ferroptosis regulated cell death pathway. In addition, she works on the characterization and development of natural products and derivatives thereof for the treatment of acute and chronic neurological disorders including Alzheimer's disease. Dr. Pamela Maher is searching for compounds that could slow or stop the progression of neurodegenerative diseases, with a focus on Alzheimer's disease. Her novel approach uses compounds derived from natural products such as strawberries, turmeric, and cannabis to treat the cellular aging and memory loss seen in Alzheimer's disease. Maher and her team discovered a new cell death pathway called oxytosis/ferroptosis and were among the first to consider aging in the discovery of drugs for Alzheimer's disease.

### **Medicinal Cannabis**

**Senior Professional Development Researcher, Pharmacist, Faculty Lecturer and Publicist**

**Prof. Dr. Samo Kreft, Master of Pharmacy**

**SLOVENIA - EU**

Prof. Dr. Samo Kreft is a full professor at the Faculty of Pharmacy of the University of Ljubljana, where he researches medicinal plants and other medicines of natural origin and lectures on them to students. He has also held professional positions at the European Medicines Agency in London. He has published more than 100 original scientific articles in renowned scientific journals.

In addition to scientific articles, he has written more than 70 popular and professional articles and is a regular guest on television and radio shows. Dr. Kreft was the editor of several books, such as *Sodobna fitoterapija*, which has already sold more than 3,000 copies; *Food supplements*, which was published by the reputable foreign publishing house Elsevier; *Kvarkadabra in the kitchen*; *Ayurveda – a new way for healthy life in Europe*. He is interested in medicinal plants, primarily cannabis, because they intertwine the research fields of botany, chemistry, ecology, medicine, as well as ethnology and history. He is fascinated by the blurred boundaries between the researched and the unexplored, the proven and the traditional, the official and the alternative. He is the editor of the website MODERN PHYTOTHERAPY.

## **Medicinal Cannabis & Hemp**

Senior Professional NGO lobbyist, international law proponent, global public interest law advocate and strategic leader of global projects

### **M.Sc. Majda Robić**

#### **SLOVENIA – EU**

Before the European Parliament, the European Commission and the United Nations, as well as before numerous embassies, Ms. Robić Majda, as an international lobbyist and NGO representative and head of Slovenian, European and international projects, among other things, independently advocates for the importance of industrial hemp, cannabinoids and medical cannabis, in equal and professional interest. With her work team, she achieves key breakthroughs and global achievements that represent a key contribution to global development, economy and human and environmental health, also before 60 countries of the United Nations - UN, where she leads global negotiations and NGO lobbying for medical cannabis and CBD, where with the 2023 team, they reach a final key binding global agreement. In Slovenia, she leads the National Cannabis Working Team of the Republic of Slovenia, which, under her leadership, introduced legislation for the marketing, development and production of industrial hemp products and professionally participated in the establishment of the Cannabis for Medical and Scientific Purposes Act (ZKMZN). For more than 15 years, she has been the president of the Pomurje Herbalists' Association in the public interest and is the executive director of WORLD HEMP CONGRESS, GLOBAL medicinal cannabis INNOVATIONS, GLOBAL HEMP INNOVATION, GLOBAL HEMP tech INNOVATION, GLOBAL HEMP food INNOVATION and GLOBAL green tech INNOVATIONS, and manages the Panonia Institute where she leads the PROJECT DEVELOPMENT NETWORK and other current projects. M.Sc. Majda Robić, at the international master's level, completed the MicroMasters Certified International Master in EMA - Entrepreneurial Mind in Action in the Digital Age, which confirms her education in the field of innovation, management and preparation of international demanding projects and at the master's level, she is professionally oriented in Business Law and Lobbying in the EU, European Law, Law and Human Resources, International Economic Relations and Institutions and other broader business management development knowledge. He is upgrading his knowledge at Stanford Business University in the USA and is preparing for a doctorate in Politics and Diplomacy in Switzerland.

## **Medicinal Cannabis & Hemp**

Senior international Lawyer

### **Charles Kovess, LL.B. (Hons), LL.M., CSP, KSJ**

#### **AUSTRALIA**

Mr. Charles Kovess, graduated with honours in Law from the University of Melbourne and later obtained a Master of Laws from Monash University, has established himself as a formidable figure in the legal world. His expertise and leadership culminated in the establishment of his own law firm and later as head of the commercial law department at Barker Gosling in Australia, later specialising in medical and industrial cannabis law, and also advising organisations seeking to expand globally. From chairing the Australian-Hungarian Chamber of Commerce to contributing to various charities, his commitment to positive global impact is unwavering, as is his commitment to the cannabis sector, where he is involved in drafting Australian and international legislation in the field, developing innovation and embedding cannabis into the economic and social life of Australia and globally. He is currently the President of the Australian Industrial Hemp Association, a member of the Executive Committee of the Federation of International Hemp Organizations and an invaluable member and expert at the WORLD HEMP CONGRESS.

Kovess, today, among other things, represents one of the most prominent global business, development, ethical and investment public promoters and motivators, where he works in the recently world-class company Kovess International.

\*\*\*

**RESPONSIBLE ORGANIZER:**

**Društvo zeliščarjev Pomurje, NVO v javnem interesu**  
***Pomurje Herbalists Association, NGO in the public interest***  
**Rakičan, Lendavska 3, 9000 Murska Sobota SI-EU**  
**E: [Drustvo.Zeliscarjev.Pomurje@gmail.com](mailto:Drustvo.Zeliscarjev.Pomurje@gmail.com)**  
**E: [WORLD.HEMP.CONGRESS@gmail.com](mailto:WORLD.HEMP.CONGRESS@gmail.com)**